| Amsterdam | |
| 178 | |
| Probiodrug AG is a biopharmaceutical company focused on the development and commercialisation of new therapeutic products for the treatment of Alzheimers disease (AD). Today Probiodrugs aim is to become a leading company in the development of Alzheimers treatments and to thereby provide a better life for patients. Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight AD. |
|
| Probiodrug is developing drug candidates to specifically target toxic pyroglutamate-Abeta (pGlu-Abeta) via two complementary modes of action: (i) inhibition of Glutaminyl Cyclase (QC), thus inhibiting the production of pGlu-Abeta; and (ii) clearing existing pGlu-Abeta from the brain. Probiodrugs current development pipeline consists of the following product candidates: PQ912 small molecule QC inhibitor (phase2) PBD-C06 pGlu-Abeta specific mAB (preclinical) |
|
| GLUND Konrad | |
| www.probiodrug.de |
Fiche créée le 10/04/2016 par 
Guillaume vue 5 fois.